| This is the talk page for discussing improvements to the Pomalidomide article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pomalidomide.
|
Discovered in 2001 ?
editIn this reference [1] it's mentioned that both pomalidomide and lenalidomide went into clinical trials in 1999. So it's impossible it was invented in 2001. Discuss?
- ^ Quach, H (12 November 2009). "Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma". Leukemia. 24 (1): 22–32. doi:10.1038/leu.2009.236.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help)
HlynurT (talk) 13:20, 15 September 2012 (UTC)
- Structure activity studies with hundred of compounds were done from 1994 to 2000 in the D'Amato lab. The results with amino-thalidomide were finally published in the papers in 2001 and 2002, which described the dual anti-angiogenic and anti-myeloma activity. The 2001/2002 papers are the first report of this anti-myeloma activity, but the compound was identified long before the final publication. The company wanted to keep results confidential until the phase I clinical trials were established. — Preceding unsigned comment added by 108.49.217.240 (talk) 20:05, 9 February 2013 (UTC)
When patented ?
edit2 US patents expiring July 2016 : 5,635,517 and 6,476,052 - Rod57 (talk) 22:16, 11 August 2016 (UTC)